Company: PTPI
Filing Date: 2025-03-14
Form Type: PRER14A
Source: 0001104659-25-024012
Chunk: 53

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-14
Form: PRER14A
Chunk 53
---

Plan. Shares of the Company’s Common Stock that are surrendered in payment of the exercise price of an option (including an option
granted under the Prior Plans) or a stock appreciation right will not again be available for issuance under the 2020 Plan. Shares of
the Company’s Common Stock that are withheld in satisfaction of the withholding taxes, or surrendered for the payment of taxes,
incurred in connection with the issuance, vesting, or exercise of any award (including an option granted under the Prior Plans), or the
issuance of the Company’s Common Stock will not be available for issuance under the 2020 Plan. When stock appreciation rights are
granted, the full number of shares subject to the stock appreciation rights will be considered issued under the 2020 Plan regardless
of the number of shares issued upon exercise of the stock appreciation rights. If the Company repurchases shares of the Company’s
Common Stock on the open market with the proceeds from the exercise price the Company receives from options (including options granted
under the Prior Plans), the repurchased shares will not be available for issuance under the 2020 Plan. If any awards are paid in cash,
and not in shares of the Company’s Common Stock, any shares of the Company’s Common Stock subject to such awards will also
be available for future awards. In addition, shares of the Company’s Common Stock issued under awards made pursuant to assumption,
substitution, or exchange of previously granted awards of a company that the Company acquires will not reduce the number of shares of
the Company’s Common Stock available under the 2020 Plan. Available shares under a stockholder approved plan of an acquired company
may be used for awards under the 2020 Plan and will not reduce the share reserve, subject to compliance with the applicable stock exchange
requirements and the Code.

The maximum aggregate grant
date value of shares of Common Stock subject to awards made to any non-employee director during any calendar year for services rendered
as a non-employee director shall not exceed $1,000,000 in total value. In determining this dollar limit, the value of awards will be
calculated based on the grant date fair value of the awards for financial reporting purposes.

Adjustments

In connection with stock
splits (reverse stock splits), stock dividends, recapitalizations, and certain other events affecting the Company’s Common Stock,
the committee will make adjustments as it deems appropriate including, without limitation, in (i) the maximum number of shares of